Strides Pharma Science controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile1 entries
2020
Strides Pharma recalls Tacrolimus capsules in the US
Recall announced
Strides Pharma Inc, a subsidiary of Strides Pharma Science, initiated a recall in the United States of 960 bottles of Tacrolimus capsules. The recall followed the FDA citing failed moisture limits for the product. The FDA classified the recall as Class III.
Company response
Recall — Strides Pharma Inc
The company has initiated the countrywide recall of the affected lot on December 22, 2020.
Source excerpt
The company has initiated the countrywide recall of the affected lot on December 22, 2020.
In a separate statement, the USFDA said Strides Pharma Inc, a subsidiary of Bengaluru-based Strides Pharma Science, is recalling 960 bottles of Tacrolimus capsules (100mg) due to "failed moisture limits".